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Thirteen U.S. and European studies have documented the benefits of blood glucose awareness training (BGAT) ([@r1]). These benefits include improvements in detecting and reducing the occurrences of extreme blood glucose levels and their sequelae, e.g., reducing occurrence of ketoacidosis, severe hypoglycemia, hypoglycemia-related driving mishaps, and fear of hypoglycemia. We hypothesized that an internet version of BGAT would be perceived as useful, be completed efficiently, and produce greater clinical benefits compared with a wait-list control group.

RESEARCH DESIGN AND METHODS
===========================

A notice in *Diabetes Forecast* inviting participants to evaluate BG*AT*home.com resulted in 210 individuals completing an online screening in 10 days. Participants were the first 40 individuals who, by telephone interviews, met the following inclusion criteria: type 1 diabetes, routinely measuring blood glucose levels more than twice a day, and willingness to devote 1--2 h/week for 8--10 weeks to completing BG*AT*home. Of 108 responders telephoned, 38 were unreachable, 14 were ineligible, and 10 declined participation ([Table 1](#t1){ref-type="table"}).

After signing institutional review board--approved informed consent, participants were mailed a handheld computer (HHC) and a LifeScan One-Touch meter with supplies for one month\'s use. Participants were instructed to *1*) activate the HHC before performing routine self monitoring of blood glucose (SMBG); *2*) enter an estimate of their current blood glucose level; *3*) based on this estimate, indicate whether they should then eat fast-acting carbohydrates, engage in vigorous exercise, or drive; and *4*) perform SMBG and record their actual blood glucose levels. After returning the HHC, participants completed online a demographic questionnaire, the Diabetes Knowledge Scale, and the Hypoglycemia Fear Survey ([@r2]). The HHC and questionnaire data were collected again 12 weeks later, along with Likert-scale items assessing BG*AT*home\'s benefits and usability.

Users were given 12 weeks to complete BG*AT*home\'s units, detailed elsewhere ([@r1]). Central to BGAT is completing daily blood glucose diaries, in which participants *1*) record relevant blood glucose information and symptoms, *2*) estimate their current blood glucose, *3*) receive feedback on their estimate accuracy by performing and recording SMBG, *4*) interpret the clinical significance of their accuracy with the error grid ([@r2]), and *5*) anticipate their blood glucose level 1 h later. To encourage use of blood glucose diaries, participants were only given access to the next unit 7 days following completion of the previous unit.

With internet delivery to a heterogeneous sample, individuals would be expected to pursue BGAT for various reasons. Thus, the primary outcome variable would need to incorporate a variety of possible desired outcomes. Consequently, our Improved Functioning Score (IFS) is a composite score where assessment-dependent variables are converted to *Z* scores. Assessment 2 performance was converted to *Z* scores based on assessment 1\'s mean and SD. *Z* scores for each outcome variable were totaled, where zero reflects average baseline functioning for all variables and +1 reflects performance across all variables one SD above the sample\'s baseline mean ([@r3]). It incorporated the following variables from questionnaires: Diabetes Knowledge Scale (percent correct) and Hypoglycemic Fear Survey (sum of Worry subscale). It also incorporated the following variables from the HHC: percent SMBG readings within target range (3.9 −10.0 mmol/l), number of undetected blood glucose readings \<3.9 mmol/l, overall blood glucose estimation accuracy (Accuracy Index) ([@r4]), when blood glucose levels are \<3.9 mmol/l, number of risky decisions to drive, not eat fast-acting carbohydrates, and exercise.

RESULTS
=======

Two wait-list control group participants and one BG*AT*home participant dropped out during the treatment period. Two BG*AT*home participants dropped out during assessment 1.

ANOVA demonstrated that BG*AT*home resulted in greater improvement in IFS: interaction F(1,33) = 4.20; *P* = 0.048 ([Table 1](#t1){ref-type="table"}). On a scale of 1--5 in which 1 = Not at all and 5 = Very, treatment participants rated BG*AT*home as beneficial, easy to use, and enjoyable (3.8 ± 1.17, 3.9 ± 0.73, and 3.8 ± 1.04, respectively).

On average, participants completed BG*AT*home in 11 weeks, logged onto BG*AT*home.com 30.4 ± 16.51 times, and spent 26.4 ± 16.3 min on each unit. These measures of use indicate trends toward a relationship between more website use and increased benefits. More time spent on units was associated with greater IFS improvement (*r* = −0.36, *P* = 0.10). More frequent log-ons were associated with greater improvement in knowledge (*r* = 0.49, *P* = 0.03) and lower blood glucose levels \<50 mg/dl (*r* = −0.54, *P* = 0.02). Age was not correlated with IFS improvement; however, education tended to be associated with improved IFS (*r* = 0.45, *P* = 0.07).

CONCLUSIONS
===========

BG*AT*home was found to be beneficial, easy to use, and enjoyable. This is the first time BGAT was made available to individuals with various goals, needs, diabetes regimens, and resources. Despite this heterogeneity, BG*AT*home improved performance, summed across all eight dependent variables an average of 2.37 SDs.

Greater BG*AT*home use appeared to yield improved benefits. Engagement might be further enhanced by *1*) incorporating a chat room where users share experiences and support; *2*) employing a group context, led by a diabetes educator ([@r5]); *3*) undergoing an initial motivational interview ([@r6]); *4*) fiscally investing in training; and *5*) having a pressing personal goal, such as achieving tight metabolic control because of pregnancy without increasing risk of severe hypoglycemia ([@r7]) or following a costly hypoglycemia-related driving mishap.

While our final participant sample came from 35 different U.S. cities and 21 different states, allowing greater external validity, the sample size and its demographic composition (white, middle-aged, educated individuals) was a limitation of this study. A larger, more representative sample would also allow investigation into the role of socioeconomic status, race, and education.

Nevertheless, this study indicates the possible benefits of disseminating BG*AT*home over the internet in a personalized and self-directed format, serving a large number of individuals in a cost-effective manner.
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###### 

Demographics of participants in the waiting-list control and BG*AT*home groups

                                                                                           Waiting-list control group   BG*AT*home.com group        Comparison values
  ---------------------------------------------------------------------------------------- ---------------------------- --------------------------- -------------------------------
  Demographics                                                                                                                                      
      Sample size (*n)*                                                                    18                           17                          
      Age (years)                                                                          52.7 ± 13.96                 43.7 ± 14.06                *F*(1,33) = 3.79, *P* \< 0.07
      Sex (% female)                                                                       56                           59                          χ^2^ = 0.04, *P* \< 0.85
      Race (% white)                                                                       100                          100                         
      Years of education                                                                   15.3 ± 1.71                  16.1 ± 1.93                 *F*(1,33) = 1.86, *P* \< 0.19
      Married                                                                              78                           71                          χ^2^ = 1.13, *P* \< 0.57
      Age at diagnosis (years)                                                             26.3 ± 16.24                 18.9 ± 8.86                 *F*(1,33) = 2.79, *P* \< 0.11
      Height (in)                                                                          66.6 ± 13.73                 67.6 ± 4.15                 *F*(1,33) = 0.54, *P* \< 0.47
      Weight (lbs)                                                                         163.2 ± 30.99                178.3 ± 47.32               *F*(1,33) = 1.26,*P* \< 0.28
  Dependent variables pre- to posttreatment                                                                                                         
      Decisions to east fast-acting carbohydrates when blood glucose is \<3.9 mmol/l (%)   35 (25.4) to 25 (30.7)       36 (25.0) to 45 (30.9)      *F*(1,24) = 3.73, *P* \< 0.07
      Decisions not to drive when blood glucose is \<3.9 mmol/l (%)                        57 (28.2) to 52 (36.5)       45 (32.6) to 59 (34.1)      *F*(1,24) = 2.46, *P* = 0.13
      IFS                                                                                  0.46 (3.8) to 0.60 (4.0)     −0.49 (4.0) to 1.87 (4.1)   F(1,33) = 4.20, *P* \< 0.05

Data are means ± SD or percent.
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